Category:

Release – BioSig’s PURE EP System to be Featured During EPLive 2022

Posted on by Admin



BioSig’s PURE EP™ System to be Featured During EPLive 2022

News and Market Data on BioSig Technologies

The Company’s flagship technology to be featured during a
two-day educational conference that draws the world’s top cardiac
electrophysiology experts

Westport, CT, May 25, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company advancing electrophysiology workflow by delivering greater intracardiac signal fidelity through its proprietary signal processing platform, today announced that its flagship technology will be featured during EPlive, a hybrid event taking place at St. David’s Medical Center in Austin, Texas from June 2-3, 2022.

EPLive is a two-day intensive educational meeting for practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias. During the event, BioSig will be exhibiting and offering technology demonstrations, including features of its newly released PURE EP NOVA-5 Software. Enhanced with NOVA-5 Software, the Company believes that the PURE EP(TM) System delivers a new standard in signal processing, offering greater customization and smarter workflows. Additionally, the Company will showcase the next generation of PURE EP(TM) Software Modules currently in advanced development stages.

The concept for EPLive was first created and developed by Dr. Andrea Natale, Cardiac Electrophysiologist at St. David’s Medical Center in Austin, Texas. As an internationally respected physician and leader in the field of cardiac electrophysiology, Dr. Natale is passionate about education, training and knowledge sharing when it comes to delivering the best possible care to arrhythmia patients. As the first center to commercially adopt the PURE EP(TM) System, Dr. Natale and the physicians at Texas Cardiac Arrhythmia Institute (TCAI) have performed over 500 cases with the PURE EP(TM) System since its installation in November 2019.

“We have spent approximately thirteen years working in collaboration with the physicians at TCAI to bring this important innovation to market. Our collaboration with this center of excellence has supported our company in so many positive ways and we are excited to participate in this great event,” commented Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.

To
register to attend the event, please click here.

The PURE EP(TM) is an FDA 510(k) cleared non-invasive class II device that aims to drive procedural efficiency and efficacy in cardiac electrophysiology. To date, more than 73 physicians have completed over 2,200 patient cases with the PURE EP(TM) System.

Clinical data acquired by the PURE EP™ System in a multi-center study at centers of excellence including Texas Cardiac Arrhythmia Institute at St. David’s Medical Center and Mayo Clinic was recently published in the Journal of Cardiovascular Electrophysiology and is available electronically with open access via the Wiley Online Library. Study results showed 93% consensus across the blinded reviewers with a 75% overall improvement in intracardiac signal quality and confidence in interpreting PURE EP™ signals over conventional sources.

About
EPLive
EPLive is an intensive, two-day educational meeting for practicing clinical cardiac electrophysiologists, electrophysiologist fellows and general cardiologists who have an interest in treating complex cardiac arrhythmias, a condition in which the heart beats with an irregular or abnormal rhythm. Live cases broadcast from the new, state-of-the-art Electrophysiology Center at St. David’s Medical Center, with expert commentary, will serve as the primary teaching tool. EPLive consists of four sections: Atrial Fibrillation (A Fib) ablation, Ventricular Tachycardia (VT) ablation, Devices, and New Technology. The sessions consist of a combination of live and recorded cases from TCAI and some of the world’s premier centers. Cases include procedures such as A Fib ablation and ablation of post-A Fib atrial arrhythmias, VT ablation (endocardial and epicardial), balloon cases (cryo, Apama and laser), CRT implants, SQ ICD and lead extraction and venoplasty. Additionally, EPLive will feature new technology pioneered by physicians at TCAI, including electroporation and leadless dual chamber pacing.

About
BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company’s first product, PURE EPä System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking
Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward- looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) the geographic, social and economic impact of COVID-19 on our ability to conduct our business and raise capital in the future when needed, (ii) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (iii) difficulties in obtaining financing on commercially reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more key executives or scientists; and (vi) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise. 


Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880, US
aballou@biosigtech.com
203-409-5444, x119
 

 


Improving Metal Properties to Improve Product Design and Function

Posted on by Admin 


Image Credit: MIT Research


Researchers Unveil a Secret of Stronger Metals

David L. Chandler | MIT
News Office

Forming metal into the shapes needed for various purposes can be done in many ways, including casting, machining, rolling, and forging. These processes affect the sizes and shapes of the tiny crystalline grains that make up the bulk metal, whether it be steel, aluminum or other widely used metals and alloys.

Now researchers at MIT have been able to study exactly what happens as these crystal grains form during an extreme deformation process, at the tiniest scales, down to a few nanometers across. The new findings could lead to improved ways of processing to produce better, more consistent properties such as hardness and toughness.

The new findings, made possible by detailed analysis of images from a suite of powerful imaging systems, are reported today in the journal Nature Materials, in a paper by former MIT postdoc Ahmed Tiamiyu (now assistant professor at the University of Calgary); MIT professors Christopher Schuh, Keith Nelson, and James LeBeau; former student Edward Pang; and current student Xi Chen.

“In the process of making a metal, you are endowing it with a certain structure, and that structure will dictate its properties in service,” Schuh says. In general, the smaller the grain size, the stronger the resulting metal. Striving to improve strength and toughness by making the grain sizes smaller “has been an overarching theme in all of metallurgy, in all metals, for the past 80 years,” he says.

Metallurgists have long applied a variety of empirically developed methods for reducing the sizes of the grains in a piece of solid metal, generally by imparting various kinds of strain through deforming it in one way or another. But it’s not easy to make these grains smaller.

The primary method is called recrystallization, in which the metal is deformed and heated. This creates many small defects throughout the piece, which are “highly disordered and all over the place,” says Schuh, who is the Danae and Vasilis Salapatas Professor of Metallurgy.  

When the metal is deformed and heated, then all those defects can spontaneously form the nuclei of new crystals. “You go from this messy soup of defects to freshly new nucleated crystals. And because they’re freshly nucleated, they start very small,” leading to a structure with much smaller grains, Schuh explains.

What’s unique about the new work, he says, is determining how this process takes place at very high speed and the smallest scales. Whereas typical metal-forming processes like forging or sheet rolling, may be quite fast, this new analysis looks at processes that are “several orders of magnitude faster,” Schuh says.

“We use a laser to launch metal particles at supersonic speeds. To say it happens in the blink of an eye would be an incredible understatement, because you could do thousands of these in the blink of an eye,” says Schuh.

Such a high-speed process is not just a laboratory curiosity, he says. “There are industrial processes where things do happen at that speed.” These include high-speed machining; high-energy milling of metal powder; and a method called cold spray, for forming coatings. In their experiments, “we’ve tried to understand that recrystallization process under those very extreme rates, and because the rates are so high, no one has really been able to dig in there and look systematically at that process before,” he says.

Using a laser-based system to shoot 10-micrometer particles at a surface, Tiamiyu, who carried out the experiments, “could shoot these particles one at a time, and really measure how fast they are going and how hard they hit,” Schuh says. Shooting the particles at ever-faster speeds, he would then cut them open to see how the grain structure evolved, down to the nanometer scale, using a variety of sophisticated microscopy techniques at the MIT.nano facility, in collaboration with microscopy specialists.

The result was the discovery of what Schuh says is a “novel pathway” by which grains were forming down to the nanometer scale. The new pathway, which they call nano-twinning assisted recrystallization, is a variation of a known phenomenon in metals called twinning, a particular kind of defect in which part of the crystalline structure flips its orientation. It’s a “mirror symmetry flip, and you end up getting these stripey patterns where the metal flips its orientation and flips back again, like a herringbone pattern,” he says. The team found that the higher the rate of these impacts, the more this process took place, leading to ever smaller grains as those nanoscale “twins” broke up into new crystal grains.

In the experiments they did using copper, the process of bombarding the surface with these tiny particles at high speed could increase the metal’s strength about tenfold. “This is not a small change in properties,” Schuh says, and that result is not surprising since it’s an extension of the known effect of hardening that comes from the hammer blows of ordinary forging. “This is sort of a hyper-forging type of phenomenon that we’re talking about.”

In the experiments, they were able to apply a wide range of imaging and measurements to the exact same particles and impact sites, Schuh says: “So, we end up getting a multimodal view. We get different lenses on the same exact region and material, and when you put all that together, you have just a richness of quantitative detail about what’s going on that a single technique alone wouldn’t provide.”

Because the new findings provide guidance about the degree of deformation needed, how fast that deformation takes place, and the temperatures to use for maximum effect for any given specific metals or processing methods, they can be directly applied right away to real-world metals production, Tiamiyu says. The graphs they produced from the experimental work should be generally applicable. “They’re not just hypothetical lines,” Tiamiyu says. For any given metals or alloys, “if you’re trying to determine if nanograins will form, if you have the parameters, just slot it in there” into the formulas they developed, and the results should show what kind of grain structure can be expected from given rates of impact and given temperatures.

The research was supported by the U.S. Department of Energy, the Office of Naval Research, and the Natural Sciences and Engineering Research Council of Canada.

 

Reprinted with permission of MIT News (http://news.mit.edu/)


Suggested Content



Prosthetic Touch Signal Back to the Brain Hits a Glitch

Elon Musk Talks About Tesla Bots, Birth Rates, and Federal Incentives





Powerful Technologies Borrowed from Nature



Small-Cap Stock Category Sees Most Insiders Buying Since Spring of 2020

 

Stay up to date. Follow us:

 

Nasdaq Listed Biotech Companies Under $160M Market Cap

Posted on by Admin


Nasdaq Listed Biotechnology Companies Under $160M Market Cap 

With Cash & Equivalents – Cash above Market Cap – Trading % of Cash

Download
the Excel File from Noble

This document is provided by NobleLSP, a division of Noble Capital Markets, Inc.

Financial data is sourced from CapitalIQ, and is up-to-date as of 5/18/2022.

No investment decision should be based upon the content of this document.  You should always consult an investment professional and consider the risk and suitability of any investment.

Noble Capital Markets publishes research on the following companies contained in the document: Tonix Pharmaceuticals, Genprex, PDS Biotechnology, Axcella Health

The following research disclosures pertain to these companies :

“The Company in this report is a participant in the Company Sponsored Research Program (“CSRP”); Noble receives compensation from the Company for such participation. No part of the CSRP compensation was, is, or will be directly or indirectly related to any specific recommendations or views expressed by the analyst in this research report.”

“Noble intends to seek compensation for investment banking services and non-investment banking services (securities and non-securities related) within the next 3 months.”

Please refer to the most recent research report published on each company (linked above) for up-to-date company specific disclosures.

Download
the Excel File from Noble

What Investors Haven’t Yet Noticed About the Value in Some Biotechs

Posted on by Admin 


Image Credit: Karolina Grabowska (Pexels)


When Stocks in a Sector are Trading for Less than Their Cash on Hand, it May be Time to Bargain Hunt

If you’re shopping for a wallet and one comes complete with $100 worth of cash inside and is priced at $60, would you think there is value to this purchase? A situation similar to this has evolved in many biotech stocks. Their balance sheet cash and cash equivalents exceed their market value. Whether the broader market recognizes the value in these companies and pushes prices up, or large-pharma, currently flush with cash, swoops in to own more than their purchase price, remains to be seen. But, the value many of these firms offer is more than just their R&D, patents, or product pipeline. It is also measurable assets in excess of where the market currently values the company.

Background

The Nasdaq Small-Cap Biotech Index did well beginning March 20, 2020.  At the time the race was on for a vaccine for the novel coronavirus and attention was being paid to these smaller, more nimble firms. The index rose from a low on March 20 of 2,667 to reach a high of 7,052 on February 5, 2021, just after vaccines began being distributed. That’s a 164% increase in 10 months. During that period, if you were a biotech firm, raising capital was easier than it had been in years.

From February 2021, the index began a long slide and is actually cheaper than it had been before the initial run-up. The index is now at 2,437 (May 25).

Valuations

Number crunchers at Noble Capital Markets created a list of all Nasdaq-listed biotech companies with Market Caps below $160 million. They then netted the market cap from the corporate cash position on each. The results are surprising. The list of companies is 267 long, and more than half (135), held cash and equivalents that exceeded their market value.

While a full evaluation of any company, including its cash burn rate, and future prospects is necessary, by this one measure, there are a number of potential positive outcomes for these seemingly undervalued companies.  

First, investors could begin to recognize value. As institutional and retail investors begin to become aware of the value in this sector, they may begin allocating more to small-cap biotechs.

The second is that big pharma is flush with cash. Their cumulative position is now over $300 billion. The entire group of companies with more cash than market cap has a combined market cap of $6.5 billion (values shown in green on the linked
spreadsheet). (Note: the linked spreadsheet is available exclusively for Channelchek members. Registration is free)

Third, the FDA has more free time. The pandemic put the arm of the FDA that reviews and approves new drugs and vaccines under more pressure than normal. Those resources are presumably more available now to review and approve non-pandemic-related applications.

Fourth medicine and therapies are largely recession-proof. Keeping money out of the stock market exposes investors to the erosion of an 8% inflation rate. Money in the market exposes investors to stocks that are still, by many measures overvalued. The biotech sector is not guaranteed to be revived anytime soon, but the case that it is overvalued is a tough one to make in light of the assets vs. price of these corporations.

Examples

While there are 267 companies that met the criterion, 135 had cash exceeding market value. Below are three examples as a demonstration of what is included on the spreadsheet:

 Eledon (ELDN) has a market value of 57% of its cash position. In actual dollar amounts, it has a market cap of $43.6 million, and current cash assets of $76.7 million. ELDN is a clinical-stage pharmaceutical company focusing on developing medicines for patients living with autoimmune diseases and requiring an organ or cell-based transplant.

ELDN is currently trading at $3.11 per share.

Tonix Pharmaceuticals (TNXP) has a market value of $39.9 million. According to its March 31, 2022 10-Q, Tonix has $140.4 million in cash and equivalents. This causes cash to be 350% of market value. Tonix is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering.

TNXP is currently trading at $1.94 per share.

Sigilon Therapeutics (SGTX)  has a market value of $25.8 million. The company’s cash position is $107.1 million which is 314% of the market value. Sigilon is a clinical-stage biopharmaceutical company. It’s developing a new class of therapeutics and functional cures for patients with chronic diseases by providing stable and durable levels of therapeutic molecules.

SGTX is currently trading at $0.74 per share.

 

Take-Away

For a brief moment in 2020, oil prices were so low that oil futures were negative – you could actually get paid to own an oil contract. Some months after this situation, the entire energy sector became the best performing industry. It still is. Small-cap biotech may now be experiencing its own oversold conditions.

An investment in some companies is backed by more cash and other assets than it would cost the investor or acquirer. There are four companies on the linked list trading at a level where the net cash is four times the market cap.

The biotech sector appears ripe for attention by bottom-pickers.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Food Costs, Empty Shelves, and Real Estate Prices Could Provide Investors With Opportunities

Energy and Global Fundamentals Make a Good Case for Owning Western Uranium Stocks




Where are Consumers Most Likely to Spend Their Leisure Budget?

Small-Cap Stock Category Sees Most Insiders Buying Since Spring of 2020

Sources

https://channelchek.com/news-channel/Nasdaq_Listed_Biotech_Companies_Under_$160M_Market_Cap

www.channelchek.com

Stay up to date. Follow us:

 

Tonix Pharmaceuticals (TNXP) – Monkeypox Cases Attract Attention To The Tonix Vaccine Programs

Posted on by Admin

Tuesday, May 24, 2022

Tonix Pharmaceuticals (TNXP)
Monkeypox Cases Attract Attention To The Tonix Vaccine Programs

Tonix is a clinical-stage biopharmaceutical company focused on discovering, licensing, acquiring and developing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Tonix’s portfolio is composed of immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. Tonix’s immunology portfolio includes biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-15001 which is a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. A Phase 1 study of TNX-1500 is expected to be initiated in the second half of 2022. Tonix’s rare disease portfolio includes TNX-29002 for the treatment of Prader-Willi syndrome. TNX-2900 has been granted Orphan-Drug Designation by the FDA. Tonix’s infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox called TNX-8013, next-generation vaccines to prevent COVID-19, and an antiviral to treat COVID-19. Tonix’s lead vaccine candidates for COVID-19 are TNX-1840 and TNX-18504, which are live virus vaccines based on Tonix’s recombinant pox vaccine (RPV) platform. TNX-35005 (sangivamycin, i.v. solution) is a small molecule antiviral drug to treat acute COVID-19 and is in the pre-IND stage of development. TNX-102 SL6, (cyclobenzaprine HCl sublingual tablets), is a small molecule drug being developed to treat Long COVID, a chronic post-acute COVID-19 condition. Tonix expects to initiate a Phase 2 study in Long COVID in the second quarter of 2022. The Company’s CNS portfolio includes both small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Tonix’s lead CNS candidate, TNX-102 SL, is in mid-Phase 3 development for the management of fibromyalgia with a new Phase 3 study launched in the second quarter of 2022. Finally, TNX-13007 is a biologic designed to treat cocaine intoxication that is expected to start a Phase 2 trial in the second quarter of 2022. TNX-1300 has been granted Breakthrough Therapy Designation by the FDA.

Robert LeBoyer, Vice President, Research Analyst, Life Sciences , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Cases Of Monkeypox Infection Have Been Reported in US.  Monkeypox infections have recently been reported in the US and around the globe.  Although rarely seen outside of parts of Africa, an estimated 190 cases have been reported in 16 countries outside of territories where it is normally found.  Although there is little chance of widespread infection in the US, the outbreak has drawn attention to companies developing vaccines for monkeypox, smallpox, and biodefense programs.

Tonix Has A Proprietary Vaccine Program For Monkeypox and Smallpox.  Although smallpox has been eradicated, it has been identified as one of several viruses that could be used for bioterrorism. There is an approved smallpox vaccine (Jynneos, from Bavarian Nordic), although it has safety and tolerability concerns including pain, swelling, severe allergic reactions.  TNX-801 is in development to be an effective and better tolerated smallpox vaccine….

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Release – Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Posted on by Admin



Ocugen Announces New Cell Therapy Program Following FDA Regenerative Medicine Advanced Therapy (RMAT) Recognition

Research, News, and Market Data on Ocugen

NeoCart® (autologous chondrocyte-derived neocartilage) receives regulatory designation intended to help expedite development of new regenerative medicines

MALVERN, Pa., May 24, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals, and vaccines, today announced that it is diversifying its innovative pipeline by introducing a Phase 3, cell therapy platform technology called NeoCart® (autologous chondrocyte-derived neocartilage). Recently, the U.S. Food and Drug Administration (FDA) granted a Regenerative Medicine Advanced Therapy (RMAT) designation to NeoCart® for the repair of full-thickness lesions of the knee cartilage in adults.

NeoCart® is a three-dimensional tissue-engineered disc of new cartilage that is manufactured by growing chondrocytes – the cells responsible for maintaining cartilage health – derived from the patient on a unique scaffold. NeoCart® has the potential to accelerate healing and reduce pain by rebuilding a patient’s damaged knee cartilage. It treats pain at the source, creating a similar, functional joint surface as it was before the injury. Ultimately, the goal is to prevent a patient’s progression to osteoarthritis. NeoCart® was acquired as a part of Ocugen’s reverse merger with the original developer of the therapy, Histogenics, in 2019.

“We’re excited that NeoCart® has received this RMAT designation, an important regulatory milestone, especially as we view this product as an enabling technology in cell and regenerative therapy for orthopedic indications. Our next step will be working with the FDA to construct the Phase 3 program to bring this innovation to this emerging treatment area,” said Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder, Ocugen, Inc. “People living with articular cartilage lesions literally have holes in their knees that are extremely difficult to heal, and without proper treatment, they’re at high risk of getting osteoarthritis. We believe that NeoCart® offers the potential for an innovative new option where treatments in this area are still limited and results are not optimal.”

The Regenerative Medicine Advanced Therapy (RMAT) designation is part of the 21st Century Cures Act. The program was created to expedite the development and review of regenerative medicine therapies intended to treat, modify, reverse or cure a serious condition. Receiving an RMAT designation offers sponsor companies all the benefits of the fast track and breakthrough therapy designation programs, including early interactions with the FDA. Ocugen is working with the FDA to finalize the Phase 3 protocols necessary to advance the clinical development program of NeoCart® required for eventual market authorization.

        

Articular cartilage lesions are a serious and often mobility-limiting condition. When the cartilage is healthy, it makes movement easy, allowing the bones to glide over each other with very little friction, but it can be damaged by injury or normal wear and tear. Cartilage that is damaged can, over time, cause pain and reduce one’s ability to function. Small articular lesions have a limited capacity to self-repair, and full thickness injuries have no ability to naturally heal. There are no blood vessels or nerves to support healing, and as cartilage matures, chondrocytes have limited ability to replicate. Untreated damage eventually can lead to osteoarthritis.

Details of the NeoCart® development program will be shared at a future date.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologicals and vaccines that improve health and offer hope for people and global communities. We are making an impact through courageous innovation, taking science in new directions in service of patients. Our breakthrough modifier gene therapy platform has the potential to treat multiple diseases with one drug and we are advancing research in other therapeutic areas to offer new options for people with unmet medical needs. Discover more at www.ocugen.com and follow us on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of
The Private Securities Litigation Reform Act of 1995, which are subject to
risks and uncertainties. Ocugen may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should,” or other words that convey uncertainty of future events or outcomes
to identify these forward-looking statements. Such forward-looking statements
include, but are not limited to, statements about Ocugen’s intention to work
with the U.S. Food and Drug Administration (“FDA”) to finalize the Phase 3
protocols necessary to advance the clinical development program of NeoCart® (autologous chondrocyte-derived neocartilage) required for
eventual market authorization. Such statements are subject to numerous
risks and uncertainties that could cause actual results to differ materially
from those expressed or implied by such statements, including, among other
things, the uncertainties inherent in research and development, including the
ability to meet anticipated clinical endpoints, ability to timely enroll clinical
trial participants, commencement and/or completion dates for clinical trials,
regulatory submission dates, regulatory approval dates and/or launch dates,
Ocugen’s ability to utilize accelerated FDA review designations, such as the
Regenerative Medicine Advanced Therapy designation, which does not guarantee an
accelerated pathway or timeline for regulatory approval of any such product
candidates, including NeoCart® (autologous
chondrocyte-derived neocartilage), or increase the likelihood of any such approvals,
and the other risks and uncertainties more fully described in our periodic
filings with the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in the quarterly
and annual reports that we file with the SEC. Any forward-looking statements
that we make in this press release speak only as of the date of this press
release. Except as required by law, we assume no obligation to update
forward-looking statements contained in this press release whether as a result
of new information, future events or otherwise, after the date of this press
release.

Ocugen Contact: 
Ken Inchausti
Head, Investor Relations & Communications
ken.inchausti@ocugen.com

For investor-related inquiries: IR@Ocugen.com


Release – Kratos Acquires Southern Research Engineering Division Adding Unique Capabilities in Hypersonic, Ballistic Missile, Space and ISR Areas

Posted on by Admin



Kratos Acquires Southern Research Engineering Division Adding Unique Capabilities in Hypersonic, Ballistic Missile, Space and ISR Areas

Research, News, and Market Data on Kratos Defense & Security Solutions

SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a leading National Security Solutions provider, announced today that it has acquired the Birmingham, Alabama based Engineering Division of Southern Research for approximately $80 million, subject to reduction based on working capital, including $75 million in cash and $5 million in shares of Kratos common stock. Southern Research’s Engineering Division (SRE) is the market leader in assisting customers in the development, modeling and deployment of advanced materials for extreme environments, including hypersonic, space, missile, missile defense, strategic deterrence, propulsion systems, and energy applications. SRE also specializes in Intelligence Surveillance and Reconnaissance (ISR) sensor development, electromechanical systems design and integration, aerospace engineering, materials engineering, artificial intelligence and machine learning, directed energy, RF systems design and integration, advanced manufacturing, and computational sciences.

Approximately 25 percent of the SRE purchase price was paid for the one-of-a-kind, unique 54-acre campus, with 102,000 square feet of laboratory, material assessment, technology, prototype development, secure, and other facilities, and the machinery and equipment needed to perform the core, sole source test and evaluation analysis and extreme environment characterization of materials for Hypersonic, Missile Defense, Strategic Deterrent, Space-related and other Systems. The balance of the purchase price represents approximately 1.6 times SRE’s historical, trailing twelve-month revenue, which includes approximately $15 million in annual ISR and other unique product development initiatives that are currently in development and expected to transition to production. The acquisition establishes Kratos SRE, a new business unit within Kratos’ Defense and Rocket Support Services Division.

The acquisition brings to Kratos a team of approximately 140 engineers, technicians and program support professionals, substantially all of which hold national security clearances. This dedicated group of professionals strengthens Kratos’ Hypersonic and Missile System-related capabilities by virtue of its market-leading advanced materials testing and evaluation capabilities and experience. The SRE group plays a unique and critical role in assisting the U.S. Government and defense industry contractors to characterize and select strategic materials for certain applications. SRE is also used widely by the space community for launch, re-entry and other vehicles, systems, and capabilities. “Kratos is the perfect home for my engineering team,” said Michael Johns, former Southern Research Vice President of Engineering and new Kratos SRE Senior Vice President. “From Hypersonics to ISR applications, Kratos brings tremendous synergies across all of our technical platforms. We have long been the leader in understanding materials in extreme environments for applications including Hypersonics, and as a result of this acquisition by Kratos, we can carry those programs all the way through flight testing and beyond, substantially increasing our total addressable market opportunity.”

Dave Carter, President of Kratos’ Defense & Rocket Support Services Division, said, “Kratos continues to lean forward to develop and acquire capabilities and solutions that expand our ability to support a diverse range of national security customers. We are very excited about the technical capabilities and synergies gained through this acquisition. Kratos SRE will continue to provide independent, unbiased laboratory and ground testing evaluation for unique and critical materials, and we will be working to expand Kratos SRE’s testing and technology maturation offerings to include affordable live fire tests using Kratos’ family of proven subscale launch vehicles. I am confident that our similar cultures and values will enable a smooth transition and lead to collaborative business opportunities with the Navy and other customers. Establishing Kratos SRE as our Advanced Concepts group demonstrates our commitment to Alabama and the growing aerospace and defense community in Birmingham.”

Eric DeMarco, Kratos’ President and CEO, said, “The acquisition of SRE enhances Kratos’ position related to the anticipated significant future funding increases for the recapitalization of Strategic Weapon Systems, including Hypersonic, Space, Strategic Deterrence, Propulsion and Missile Defense Systems. A priority of Kratos’ strategic thesis is being the market leader, and Mike and his team clearly satisfy that requirement. Once integrated with Kratos, based on recent program awards, funding under the Department of Defense’s recently approved 2022, and anticipated 2023, budget, and prospective customer acceptance of certain SRE products in development that are nearing completion, we expect an up and to the right future year-over-year organic growth trajectory for the business beginning in 2023.”

DC Advisory served as exclusive financial advisor and Maynard, Cooper & Gale, P.C. served as outside legal counsel to Southern Research in this transaction.

About Kratos
Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) develops and fields transformative, affordable technology, platforms, and systems for United States National Security related customers, allies, and commercial enterprises. Kratos is changing the way breakthrough technology for these industries are rapidly brought to market through proven commercial and venture capital backed approaches, including proactive research and streamlined development processes. At Kratos, affordability is a technology, and we specialize in unmanned systems, satellite communications, cyber security/warfare, microwave electronics, missile defense, hypersonic systems, training, combat systems and next generation turbo jet and turbo fan engine development. For more information, go to www.KratosDefense.com.

Notice
Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made based on the current beliefs, expectations, and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 26, 2021, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the U.S. Securities and Exchange Commission by Kratos.

Press
Contact:
Yolanda White
858-812-7302 Direct

Investor
Information:
877-934-4687

investor@kratosdefense.com


Release – Defense Metals Engages SRK Consulting To Design Pre-Feasibility Level Geotechnical Drilling Program at Wicheeda Rare Earth Elements Project

Posted on by Admin



Defense Metals Engages SRK Consulting To Design Pre-Feasibility Level Geotechnical Drilling Program at Wicheeda Rare Earth Elements Project

News, and Market Data on Defense Metals

VANCOUVER, BC, May 24, 2022 /CNW/ – Defense Metals Corp. (“Defense Metals” or the “Company“) (TSXV: 
DEFN) (OTCQB: DFMTF) (FSE: 35D) is pleased to announce that it has retained SRK Consulting (Canada) Inc. (“SRK“) to assist with planning and executing geotechnical drilling investigations at the Wicheeda Rare Earth Element (REE) Project during 2022.

The objective of SRK’s work will be to assist Defense Metals with planning and implementing a pre-feasibility level geotechnical field drilling program. The objective of the field program is to collect data for the subsequent analysis, and assessment of technical risks with regards to open pit slope design. SRK will assist in the planning, set-up, training, and support towards design of the geotechnical program including determining optimal drill hole locations (co-purposed with further resource drill holes where possible), data collection methods and downhole surveying.

The SRK team will be led by Project Manager Andy Thomas, P.Eng., M.Eng., a mining rock mechanics engineer with over 16 years’ experience; and Project Practice Leader, Jarek Jakubec, C.Eng., FIMMM, corporate consultant and practice leader of the SRK mining and geology group in Vancouver with experience in the mining industry since 1984. Jarek has travelled extensively to complete studies for over 160 mining projects in 36 countries. He regularly leads teams in technical or operational audits, feasibility studies, bankable due diligence studies, and is a sought-after member of geotechnical review boards for operating mines.

The purpose of the 2022 Wicheeda REE Project’s geotechnical and hydrogeological drill program is to contribute data to the advance geotechnical characterization, and the development of comprehensive structural, hydrogeological, and rock strength models to support future advanced pre-feasibility level mine planning studies. The geotechnical and hydrological drilling is expected to include, but not be limited to, acoustic/optical televiewer downhole survey, oriented drill core, field point load and laboratory-based intact rock and discontinuity strength testing, vibrating wire piezometer, and standpipe piezometer installation for hydrogeological investigations.

Kris Raffle, P.Geo, Director of Defense Metals commented: “SRK
was a natural fit to assist in the continued advancement of the Wicheeda REE
Deposit having worked so closely with the Defense Metals technical team during
the recent PEA study. SRK is well-positioned to build on the successful PEA
mine plan and guide the collection of advanced geotechnical and hydrogeological
data that will contribute to an enhanced understating of geotechnical risk and
refinement of future project development scenarios.”

About the Wicheeda REE Property

The 100% owned 2,008-hectare Wicheeda REE Property, located approximately 80 km northeast of the city of Prince George, British Columbia, is readily accessible by all-weather gravel roads and is near infrastructure, including power transmission lines, the CN railway, and major highways.

The Wicheeda REE Project yielded a robust 2021 PEA that demonstrated an after-tax net present value (NPV@8%) of $517 million, and 18% IRR1. A unique advantage of the Wicheeda REE Project is the production of a saleable high-grade flotation-concentrate. The PEA contemplates a 1.8 Mtpa (million tonnes per year) mill throughput open pit mining operation with 1.75:1 (waste:mill feed) strip ratio over a 19 year mine (project) life producing and average of 25,423 tonnes REO annually. A Phase 1 initial pit strip ratio of 0.63:1 (waste:mill feed) would yield rapid access to higher grade surface mineralization in year 1 and payback of $440 million initial capital within 5 years.

___________________________

1 Independent Preliminary Economic Assessment for the Wicheeda Rare Earth Element Project, British Columbia, Canada, dated January 6, 2022, with an effective date of November 7, 2021, and prepared by SRK Consulting (Canada) Inc. is filed under Defense Metals Corp.’s Issuer Profile on SEDAR (www.sedar.com).

 

Qualified Person

The scientific and technical information contained in this news release as it relates to the Wicheeda REE Project has been reviewed and approved by Kristopher J. Raffle, P.Geo. (BC) Principal and Consultant of APEX Geoscience Ltd. of Edmonton, AB, a director of Defense Metals and a “Qualified Person” as defined in NI 43-101. Mr. Raffle verified the data disclosed which includes a review of the sampling, analytical and test data underlying the information and opinions contained therein.  

About SRK

SRK is an independent, global network of consulting practices in over 45 countries on six continents. Its experienced engineers and scientists work with clients in multi-disciplinary teams to deliver integrated, sustainable solutions across a range of sectors – mining, water, environment, infrastructure and energy.

About Defense Metals Corp.

Defense Metals Corp. is a mineral exploration and development company focused on the acquisition, exploration and development of mineral deposits containing metals and elements commonly used in the electric power market, defense industry, national security sector and in the production of green energy technologies, such as, rare earths magnets used in wind turbines and in permanent magnet motors for electric vehicles. Defense Metals owns 100% of the Wicheeda Rare Earth Element Property located near Prince George, British Columbia, Canada. Defense Metals Corp. trades in Canada under the symbol “DEFN” on the TSX Venture Exchange, in the United States, under “DFMTF” on the OTCQB and in Germany on the Frankfurt Exchange under “35D”.

For further information, please contact:

Todd Hanas, Bluesky Corporate Communications Ltd. 
Vice President, Investor Relations 
Tel: (778) 994 8072 
Email: 
todd@blueskycorp.ca

Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this news release.

Cautionary Statement Regarding “Forward-Looking”
Information

This news release contains “forward?looking information or statements” within the meaning of applicable securities laws, which may include, without limitation, statements relating to advancing the Wicheeda REE Project, completing the geotechnical and hydrogeological drill program and the expected results and outcomes, the Company’s plans for its Wicheeda REE Project including other studies and development work, expected results and outcomes, the technical, financial and business prospects of the Company, its REE project and other matters. All statements in this news release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, including the price of rare earth elements, the anticipated costs and expenditures, the ability to achieve its goals, that general business and economic conditions will not change in a material adverse manner, that financing will be available if and when needed and on reasonable terms. Such forward-looking information reflects the Company’s views with respect to future events and is subject to risks, uncertainties and assumptions, including the risks and uncertainties relating to the interpretation of exploration results, risks related to the inherent uncertainty of exploration and cost estimates, the potential for unexpected costs and expenses and those other risks filed under the Company’s profile on SEDAR at www.sedar.com. While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Factors that could cause actual results to differ materially from those in forward looking statements include, but are not limited to, continued availability of capital and financing and general economic, market or business conditions, adverse weather and climate conditions, failure to maintain or obtain all necessary government permits, approvals and authorizations, failure to maintain community acceptance (including First Nations),  risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters), risks relating to inaccurate geological and engineering assumptions, decrease in the price of rare earth elements, the impact of Covid-19 or other viruses and diseases on the Company’s ability to operate, an inability to predict and counteract the effects of COVID-19 on the business of the Company, including but not limited to, the effects of COVID-19 on the price of commodities, capital market conditions, restriction on labour and international travel and supply chains, loss of key employees, consultants, or directors, increase in costs, delayed drilling results, litigation, and failure of counterparties to perform their contractual obligations. The Company does not undertake to update forward?looking statements or forward?looking information, except as required by law.

SOURCE Defense Metals Corp.


Small-Cap Stock Category Sees Most Insiders Buying Since Spring of 2020

Posted on by Admin 


Image Credit: Pixabay (Pexels)


Small-Cap Insider Buying Ratio Could Mean a Market Bottom is Near

There are more insiders buying at small-cap firms than there are insiders selling. This wasn’t the case in April and is still not the case for large-cap stocks where there are far more inside sellers than there are inside buyers. Insider buying is the purchase of company shares by a director, officer, or other executives with insights from the “inside.” And, it can be a good indicator of future results.

According to Verity, an investment research & data platform, as reported by Barron’s, insiders at S&P 500 firms are acting the same as they had in the first quarter, laying low and playing a game of wait and see. But this is not the case for small-cap insiders.

Large-Cap
Insider Ratio vs Small-Cap

There were 272 insiders selling shares at S&P 500 firms during April compared with 32 buyers (11.8%), according to Verity. Looking at month-to-date, there have been 225 sellers and 42 buyers (18.7%). Put another way, within the large-cap index, for May; there have been more than five sellers for every insider buying company shares.

According to Ben Silverman, Director of Research at Verity, large-cap “Insiders are, by and large, not buying,” adding “More positively, we are still seeing lower-than-typical levels of selling. There’s this unwillingness to accept the current valuations and generate liquidity at these valuations.”

Silverman sees more positive signs for small-cap stocks included in the Russell 2000. During April, there were 388 sellers and 105 buyers at firms included in the Russell Small-Cap index. For May, this has turned around. Over the past weeks, there were 327 sellers to 395 buyers. If this ratio holds, it will be the first month with more buyers than sellers since pandemic lows in March 2020.

For the week ended May 17, there were 281 buyers—the most since the week ended May 19, 2020. Even more promising, according to Verity, was the ratio of buyers to sellers, which was 2.8 to 1. The one-year average is 0.7 to 0.8, representing that there had been more sellers than buyers. Silverman says he’s encouraged that insiders at small-cap firms are buying. He noted that we’re in the early stage of insider season when most firms open their quarterly trading window.

Small-Cap
Interest

Could this indicate a market bottom is near? Referring to the small-cap insider interest, Silverman said, “We’d like to see this number continue to grow or at least not decline significantly because historically we’ve seen buying momentum either sustain or build over a three-to-five week period near market bottoms.”

With a more refined look at the sector, Silverman sees buying momentum in the industrial goods space, including transportation, machinery, and electronic equipment firms. His view is the upswing in buying activity at regional banks is a positive sign since he believes they generally have a good pulse on local economies.

Take-Away

The knowledge that insiders are purchasing company shares can signal they have confidence in the future share price of their company. It may even indicate a market bottom is near. During the month of May, the small-cap stocks captured within the Russell 2000 index saw a far higher ratio of buyers to sellers than the S&P 500 large-cap index. What’s more, the last time this confidence indicator was positive was over two years ago.

Channelchek is a small-cap stock, data, and information resource, specializing providing users a means to explore and discover opportunities among smaller companies. Start your small-cap company
research on Channelchek.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Russell Reconstitution 2022, What Investors Should Know

Avoiding the Noise and Focusing on Managing Your Investments




NobleCon18 Rebroadcast

Small-Cap Stocks and How They’re Different

Sources

https://verityplatform.com/insights/

https://www.barrons.com/articles/stock-market-recession-inflation-federal-reserve-51653328257

Stay up to date. Follow us:

 

Central Bankers’ Opinion on Crypto is Loud and Clear at Davos

Posted on by Admin 


Image: World Economic Forum (May 24, 2022)


Cryptocurrencies in the Hot Seat at World Economic Forum

Considered by some to be controversial, the annual World Economic Forum (WEF) in Davos, Switzerland, each year impacts thinking on everything from economics, health care, environmental actions, and currencies, including cryptocurrency. This year’s summit is full of crypto-related companies seeking attention and a say. Its been over two years since the last meeting because of the pandemic, since then crypto has gained a strong foothold in many of the subjects covered at the WEF. Many crypto-related stakeholders bought exhibitor space and are attending the event. Their plans to be at this Swiss ski resort were made before the recent selloff and problems with the stablecoin TerraUSD.

 

The Establishment Speaks

Change will always be fought off by whatever is currently in place until or unless it can become a part of it. Cryptocurrencies and stablecoin fall solidly in this category, and it was made loud and clear at the World Economic Forum. Below are some topics discussed and what was said:

Is Bitcoin money? “Bitcoin may be called a coin but it’s not money. It’s not a stable store of value,” said Kristalina Georgieva, managing director of the International Monetary Fund.

Is crypto a good payment system? “Cryptocurrencies are not a reliable means of payment. Someone must be responsible for the value, and it must be accepted universally as a means of exchange. It’s not,” Villeroy said, noting that some “citizens have lost trust in crypto” because of the massive volatility.

How likely is it that cryptocurrencies and stablecoins
will be used as currency? In a panel discussion, central bankers and regulators were in more or less agreement that the recent plunge of Bitcoin, Ethereum, Luna, and TerraUSD is not behavior desired in a currency.

Are Central Bank Digital Currencies likely? Some cryptocurrencies are more akin to a pyramid scheme for the digital age because they aren’t backed by real assets, explained Kristalina Georgieva. She does however believe Central Bank Digital Currencies (CBDCs) supported by governments can be stable.

François Villeroy de Galhau, a governor of the Central Bank of France, concurred, adding that governments looking to adopt digital currencies must do so in partnership with large commercial banks.

What is the real role of cryptos? Sethaput Suthiwartnarueput, a governor of the Bank of Thailand, said that Thailand has been experimenting in the world of digital currencies. But he said it “has to be clear what problem you want to solve.”

“We don’t want to see it as a means of payment,” Suthiwartnarueput said, adding that cryptos are more of an investment than a medium of exchange.

Do they see private crypto benefits? Francois Villeroy mentioned that the experiment by El Salvador to use bitcoin as legal currency shows how risky it can be to embrace cryptocurrencies.

Georgieva noted that digital money could be a “global public good” that can help people send remittances across borders. The key is for interoperability so that it is just as easy to transfer digital currencies as it is paper-backed currencies like the dollar and euro.

Timeline? Panelists wanted to be clear that it will take time for digital currencies to evolve and become mainstream for consumers, major financial institutions, and governments.

 

Take-Away

While firms involved in digital currencies were out in force during the World Economic Forum, the recent selloff in crypto values provided less strength and enthusiasm. Particularly unenthusiastic were regulators and bankers. Their presentations and forum discussions show it may be a tougher sell than many private crypto advocates may hope for.

Paul Hoffman

Managing Editor, Channelchek

Suggested Content



Has the Crypto Crunch Accelerated SEC Plans to Regulate the Market?

Is the Move Toward ESG Funds and Sustainability Fading?




The World Is HOT Right Now! – Panel Presentation from NobleCon18

Mental Wellness: Psychedelics? Panel Presentation from NobleCon18

Sources

https://www.weforum.org/agenda/2022/05/can-cryptocurrencies-become-environmentally-friendly/

https://www.cnn.com/2022/05/23/investing/davos-central-bank-digital-currencies-crypto/index.html

Stay up to date. Follow us:

 

Schwazze (SHWZ) – Continuing to Build a Leading Regional MSO

Posted on by Admin

Monday, May 23, 2022

Schwazze (SHWZ)
Continuing to Build a Leading Regional MSO

Schwazze (OTCQX:SHWZ, NEO:SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale. The Company is committed to unlocking the full potential of the cannabis plant to improve the human condition. Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector. Schwazze is passionate about making a difference in our communities, promoting diversity and inclusion, and doing our part to incorporate climate-conscious best practices.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

1Q22 Results. Revenue for the quarter totaled $31.8 million, up from $26.5 million in the fourth quarter and $19.3 million a year ago. The increase was mostly due to acquisitions as the Colorado market continued to experience softness from the 2021 COVID highs. Adjusted EBITDA was $7.9 million in the quarter. Schwazze reported an operating loss of $4.8 million and a net loss of $28.5 million, or $0.61 per share. We had forecast revenue of $35 million and net income of $1.7 million, or $0.03 per share.

One-Time Items Impact Results. First quarter 2022 COGS was impacted by $6.3 million of purchase accounting on acquisitions, compared to $2.2 million in the year ago period. One-time costs associated with acquisitions totaled $2.8 million. Below the line, results were impacted by $13.4 million of unrealized loss on derivative liabilities and a y-o-y increase in interest expense to $7.3 million from $961,282 in 1Q21.…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Stem Holdings, Inc. (STMH) – Reports Fiscal 2Q22 Operating Results

Posted on by Admin

Monday, May 23, 2022

Stem Holdings, Inc. (STMH)
Reports Fiscal 2Q22 Operating Results

Stem is a multi-state, vertically integrated, cannabis company that, through its subsidiaries and its investments, is engaged in the cultivation, processing, packaging, distribution and branding of cannabis, hemp and their derivatives, including oils, edibles, concentrates. Additionally, the Company purchases, improves, leases, operates, and invests in properties for use in the production, distribution and sales of cannabis and cannabis-infused products licensed under the laws of the states of Oregon, Nevada, California, Massachusetts, and New York. As of December 31, 2021, Stem had ownership interests in 24 state-issued cannabis licenses including nine (9) licenses for cannabis cultivation, three (3) licenses for cannabis processing, two (2) licenses for cannabis wholesale distribution, three (3) licenses for hemp production and seven (7) cannabis dispensary licenses.

Joe Gomes, Senior Research Analyst, Noble Capital Markets, Inc.

Joshua Zoepfel, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

2QFY22 Results. Stem reported net revenue of $4.1 million compared to $5.5 million last year. The sales decline reflects a decrease in sales resulting from general market conditions. Stem reported a net loss of $3.5 million, or $0.02 per share, for the quarter. In the same period last year, Stem recorded a net loss of $8.6 million, or $0.06 per share. Outstanding shares increased to 223.7 million from 137.8 million. We had projected revenue of $4.2 million and a net loss of $4.0 million, or $0.02 per share. 

Segments. While the wholesale business saw a modest increase year-over-year, retail revenue declined to $3.2 million from $6.0 million year-over-year. We attribute the drop to a combination of a soft overall cannabis market and Stem’s ongoing restructuring of its Oregon operations.…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

BioSig Technologies (BSGM) – 1Q Short Of Expectations But Signal Strength Improving

Posted on by Admin

Monday, May 23, 2022

BioSig Technologies (BSGM)
1Q Short Of Expectations But Signal Strength Improving

BioSig Technologies is a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com). The Company’s first product, PURE EP(TM) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Gregory Aurand, Senior Research Analyst, Healthcare Services & Medical Devices, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Company filed 1Q 2022. Last week BioSig released its 10-Q for 1Q 2022.  The company recorded no PURE EP unit sales in the quarter, below our expectations of three units.  The Company received strong signals from facilities, but contracts were not signed by the end of the quarter. We expect agreements in the second quarter.  Total expenses, reduced by overhead reduction, ran higher than our expected levels as the company added back staff as part of its commercial buildout and official June 1st rollout. 

ATM agreement filed. In preparation for the commercial buildout for PURE EP, and general corporate purposes, BioSig also filed an At-The-Market (ATM) agreement for up to $10 million in common stock. We had expected a capital raise in the second half of 2022.

…

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.